Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 1256 (LINC01256) is an autonomously transcribed, non-coding RNA longer than 200 nucleotides that does not overlap with protein-coding genes[1][3]. It belongs to the class of lincRNAs, which generally regulate gene expression at the transcriptional, chromatin, and RNA processing levels and are often nuclear localized[3]. These RNAs typically fine-tune expression of neighboring genes with tissue specificity and can play roles in genome organization, but there is currently no well-characterized, direct biological or disease-related function assigned to LINC01256 specifically[1][3]. LINC01256 is not classified as a therapeutically actionable target, nor has it been reported as a clinically relevant biomarker or drug target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 1256 (LINC01256).